Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses how results of the trial compare with other treatments for gBRCAm HER2-negative high-risk early breast cancer.
In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...
Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...
Ron Lanton, Partner, Lanton Law, discusses the legal and industry challenges posed by recent National Institute of Health budget cuts, diversity bans in clinical trials, and pharmaceutical supply ...
In this part of his Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, identifies strategies that pharmaceutical companies and digital health platforms can employ to ...
In a press release, Lilly chair and CEO David A. Ricks said, “Lilly's optimism about the potential of our pipeline across ...
In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, the role pharma should be ...
FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.
Results from a Phase III study in pediatric patients demonstrated that Odactra reduced the total combined rhinitis score by ...
The Alpha Cognition executive discusses recent developments that positively impact the upcoming launch for ZUNVEYL.
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing ...
In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, addresses how tariffs will affect pharmaceutical costs and which drug categories will be most affected.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback